Study #2023-0270
A phase I-III, multicenter study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status, with locally advanced, unresectable, stage III Non-Small Cell Lung Cancer.
MD Anderson Study Status
Enrolling
Treatment Agent
Alectinib, Durvalumab, Entrectinib
Description
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Small Cell Lung Cancer
Study phase:
Phase III
Physician name:
Carl Gay
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-580-2777
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.